StemCells, Inc. Announces Commencement of the Second Cohort of the Pathway(TM) Study in Cervical Spinal Cord Injury

StemCells, Inc. STEM, +0.00% a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system diseases and disorders, announced today that it has enrolled its first subject in Cohort 2 of its Phase II Pathway Study. The study is designed to assess the efficacy of the Company’s proprietary